Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Study
  • Published:

Combined oral and topical mesalazine treatment for extensive ulcerative colitis

Nature Clinical Practice Gastroenterology & Hepatology volume 3, pages 290–293 (2006)Cite this article

Abstract

Background A 32-year-old white Jewish woman was referred to our clinic in October 2002 for a second opinion on the management of her active extensive ulcerative colitis that did not respond to oral mesalazine (mesalamine) 3.6 g/day. The severity of symptoms had affected her plans to have children.

Investigations Laboratory investigations, including perinuclear antineutrophil cytoplasmic antibodies and antibodies to Saccharomyces cerevisiae, stool cultures, and sigmoidoscopy to 40 cm from the rectum, with biopsies.

Diagnosis Moderate-to-severe active extensive ulcerative colitis, unresponsive to mesalazine at 3.6 g/day.

Management Oral mesalazine 4.8 g/day and 4 g mesalazine enemas nightly.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Farrell RJ and Peppercorn MA (2002) Ulcerative colitis. Lancet 359: 331–340

    Article  Google Scholar 

  2. Alstead EM and Nelson-Piercy C (2003) Inflammatory bowel disease in pregnancy. Gut 52: 159–161

    Article  CAS  Google Scholar 

  3. Elbaz G et al. (2005) Inflammatory bowel disease and preterm delivery. Int J Gynaecol Obstet 90: 193–197

    Article  Google Scholar 

  4. Travis SP (2004) Review article: the management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther 20 (Suppl 4): 88–92

    Article  Google Scholar 

  5. Olsen KO et al. (1999) Fertility after ileal pouch–anal anastomosis in women with ulcerative colitis. Br J Surg 86: 493–495

    Article  CAS  Google Scholar 

  6. Ferrero S and Ragni N (2004) Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet 270: 79–85

    Article  CAS  Google Scholar 

  7. Hanauer S et al. (1993) Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 88: 1188–1197

    CAS  PubMed  Google Scholar 

  8. Miglioli M et al. (1990) Oral delayed-release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. Eur J Gastroenterol Hepatol 2: 229–234

    Google Scholar 

  9. Riley SA et al. (1988) Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 29: 669–674

    Article  CAS  Google Scholar 

  10. Schroeder KW et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317: 1625–1629

  11. Sninsky CA et al. (1991) Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 115: 350–355

    Article  CAS  Google Scholar 

  12. Hanauer SB et al. (2005) Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II Trial. Am J Gastroenterol 100: 2478–2485

    Article  CAS  Google Scholar 

  13. Gisbert JP et al. (2002) Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci 47: 471–488

    Article  CAS  Google Scholar 

  14. Sutherland L and MacDonald JK (2003) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. The Cochrane Database of Systematic Reviews, Issue 3, Art. No CD000543

  15. Kruis W et al. (2003) The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 1: 36–43

    Article  CAS  Google Scholar 

  16. Campieri M et al. (1990) Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol 25: 663–668

    Article  CAS  Google Scholar 

  17. Campieri M et al. (1991) Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut 32: 929–931

    Article  CAS  Google Scholar 

  18. Hanauer SB et al. (1998) Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The US PENTASA Enema Study Group. Inflamm Bowel Dis 4: 79–83

    Article  CAS  Google Scholar 

  19. Cohen RD et al. (2000) A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 95: 1263–1276

    Article  CAS  Google Scholar 

  20. Frieri G et al. (1999) Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther 13: 1413–1417

    Article  CAS  Google Scholar 

  21. Safdi M et al. (1997) A double blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92: 1867–1871

    CAS  PubMed  Google Scholar 

  22. D'Albasio G et al. (1997) Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double blind study. Am J Gastroenterol 92: 1143–1147

    CAS  PubMed  Google Scholar 

  23. Piodi LP et al. (2004) Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol 39: 154–157

    Article  CAS  Google Scholar 

  24. Paoluzi P et al. (2002) Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild–moderate relapse of ulcerative colitis: one-year randomised multicenter trial. Dig Liver Dis 34: 787–793

    Article  CAS  Google Scholar 

  25. Vecchi M et al. (2001) Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 15: 251–256

    Article  CAS  Google Scholar 

  26. Marteau P et al. (2005) Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54: 960–965

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. fellow at Beth Israel Deaconess Medical Center specializing in inflammatory bowel disease,

    Alan C Moss

  2. Clinical Director of the Inflammatory Bowel Disease Center at Beth Israel Deaconess Medical Center, and an Instructor in Medicine at Harvard Medical School,

    Adam S Cheifetz

  3. Senior Consultant at the Inflammatory Bowel Disease Center at Beth Israel Deaconess Medical Center, and Professor of Medicine at Harvard Medical School, Boston, MA, USA

    Mark A Peppercorn

Authors
  1. Alan C Moss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adam S Cheifetz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark A Peppercorn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan C Moss.

Ethics declarations

Competing interests

Dr Chiefetz is on the Speakers Bureau for Proctor & Gamble (manufacturers of Asacol) and Dr Peppercorn is on the Speakers Bureau for Axcan (manufacturers of Canasa) and Proctor & Gamble.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moss, A., Cheifetz, A. & Peppercorn, M. Combined oral and topical mesalazine treatment for extensive ulcerative colitis. Nat Rev Gastroenterol Hepatol 3, 290–293 (2006). https://doi.org/10.1038/ncpgasthep0475

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0475

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing